Table 5

Antitumor activity of paclitaxel and cisplatin in combination with ALC on different human tumor cell xenografts in nude mice

Tumor lineALCa (mg/kg)Cisplatinb (mg/kg)Paclitaxelc (mg/kg)TVI%dLethal toxicitye
NCI-H460100180/8
Lung carcinoma6550/8
1006620/8
8862/8
1008830/8
IGROV-1100210/4
Ovarian carcinoma6570/4
100676f0/5
54980/4
1005498f0/5
A2780100380/4
Ovarian carcinoma6950/5
100696f0/4
10090/5
54980/5
1005497f0/5
LoVo10000/5
Colon carcinoma54881/5
10054900/5
  • a p.o., daily × 18, starting 3 days before the cytotoxic drug.

  • b i.v., every 7th day × 3 times.

  • c i.v., every 3rd–4th day × 4 times.

  • d Tumor volume inhibition % in treated versus control mice measured 7 days after the end of treatments.

  • e Number of mice dead from toxicity/total number of mice.

  • f ns, not significant.